Table 3 - uploaded by Astrid Baalbergen
Content may be subject to copyright.
Source publication
Recurrent cervical cancer has a poor prognosis, despite the various modalities of treatment. Prognostic factors may be helpful in selecting patients who will benefit from further treatment. This review presents an outline of the many prognostic factors and their value in recurrent cervical carcinomas with respect to survival. Size and site are well...
Context in source publication
Context 1
... other significant difference in survival was demonstrated by Ijaz et al. (20), who found a 5-year survival of 51% in patients with recurrent squamous cell carcinoma treated by radiotherapy versus 14% in patients with recurrent adenocarcinoma. All studies showed a poorer 5-year survival for recurrent adenocarcinoma compared to squamous cell carcinoma (Table 3). Therefore, adenocarci- noma appears to be a negative prognostic factor for survival after recurrent cervical carcinoma. ...
Similar publications
Background: Breast and cervical cancer are the major cause of cancer death in women in our country. For many years cervical cancer was the leading cause in incidence and mortality from neoplastic diseases. In the last years, the number of cases in these two particular types of cancers has been inverted. In 2002, according to the RHNM, the number of...
p16 has been used as a surrogate marker for human papillomavirus (HPV)-related tumours. However, it remains unclear whether p16 is also a potential marker for pulmonary tumours. Herein, we report the case of an 80-year-old woman with a history of papillary squamous cell carcinoma of the uterine cervix, presenting with a left pulmonary tumour. A bro...
To explore and analyze the correlation between LncRNA TDRG1 expression degree and the prognosis of cervical carcinoma tissues. The cervical cancer tissues and para-carcinoma tissues of 106 patients with cervical carcinoma surgically removed in our hospital were chosen as specimens. LncRNA TDRG1 expression in cervical carcinoma tissues and para-carc...
Cervical cancer is a common gynecological malignancy and a frequent cause of death. Patient outcome depends on tumor stage, size, nodal status, and histological grade. Correct tumor staging is important to decide the the treatment strategy. Magnetic Resonance Imaging is accepted as a preferred imaging modality to assess the prognostic factors.
Citations
The introduction in 1987 of a national cervical screening programme in the UK led, in little more than a decade, to a halving in the incidence of cervical cancer from 16 per 100000 to 8 per 100 000 by the year 2000. Despite similar success in other developed countries, cervical cancer remains a major international problem. It is the second most common female cancer worldwide, with almost 500 000 new cases diagnosed annually and 250 000 deaths each year.The standard ofcare for early-stage disease (International Federation of Gynecology and Obstetrics [FIGO] stage IA, IB1) remains surgery. For more advanced disease chemoradiotherapy is preferred. Despite recent improvements in survival, due in the main to the introduction of chemoradiotherapy, the overall pelvic relapse rate remains significant, with the disease recurring in the pelvis in over a quarter of women. This highlights the need for continued effort to improve outcome in this disease. Five year survival rates are around 90%, 75%, 50% and 20% for FIGO stages I, IB2/II, III and IV, respectively.The challenges in treating cervical cancer are centred on improvements in survival and local control and minimising treatment-related morbidity. This chapter focuses on the evidence for current practice and highlights future research issues.The role of surgery.Surgery remains the treatment ofchoice in early-stage disease. The most widely quoted data to support this come from an article published in 1997.
Previously, the Prognostic Factor Committee of the European Society of Gynaecological Oncology (ESGO) conducted a consensus project on the prognostic factors in epithelial ovarian cancer. It consisted on a set of overviews, which were published in this Journal and a consensus meeting held in Budapest in 1999. As a continuation the CME Journal of Gynecologic Oncology set up a second project on prognostic factors in cervical carcinoma. The relevant papers appeared in volumes 6 and 8 of this Journal (2001-2003). These papers summarise the current evidence on prognostic factors in cervical cancer, trying to respond to the following key issues: 1. novel prognostic markers capable of predicting the disease outcome on the basis of the response to treatment, 2. the most significant predictors of disease-free and overall survival as well as extra-uterine spread, 3. whether combined factors exist capable of identifying both the low- and high-risk patients, and 4. the current status and utility of the prognostic factors in the management of cervical carcinoma. In the last part of this chapter two additional papers are published. This overview summarises the conclusions of the articles in this context.
Recurrent uterine or cervical cancer can be defined as the presence of a new, recurrent disease following definitive treatment with a curative intent. For cervical cancer, as with ovarian cancer, a cutoff of >6 months post-therapy is used to distinguish recurrent from residual disease (Liyanage et al. 2010). However, this time-scale is somewhat arbitrary and the distinction does not impact on management, making it less clinically relevant. The imaging of recurrent disease in endometrial carcinoma and uterine sarcoma is essentially identical, thus we employ the term “uterine cancer” herein.
Estudio cuantitativo de base poplacional. Los autores tienen como objectivo examinar
las influencias de la región, la edad y el tiempo en la mortalidad por cáncer de
cuello uterino. Las tasas de mortalidad que ocurrieron en el Estado de Santa
Catarina, entre 1996 y 2011 fueron analizados. Los datos fueron obtenidos del Sistema
de Información de Mortalidad del Ministerio de Salud, Brasil, en el año 2013. El
analisis de los datos fue realizada fundamentada en la epidemiologia descritiva. Las
tasas de mortalidad por cáncer de cuello uterino variaron desde 3,6 hasta 5,0/100.000
mujeres. Estas tasas aumentaron en los grupos de mayor edad y presentaron los valores
más altos después de 70 años. La conciencia de la mujer acerca de la importancia del
la prueba de Papanicolaou en sus evaluaciones de salud, puede ser diferente según la
edad y las regiones en las que viven. La frecuencia de la prueba de Papanicolaou debe
cambiar mediante la observación de la evolución de las tasas de mortalidad en el
tiempo.
Aim: To identify pathological and clinical prognostic factors that best predict 5 year survival among patients with early stage cervical carcinoma treated with radical hysterectomy.
Methods: Data from 77 patients diagnosed at Safdarjung Hospital, New Delhi, India with carcinoma cervix were taken from 1997 to 2002. Patients were followed up for 5 years. Survival probability was calculated through Kaplan–Meier method for overall survival at 5 years. Univariate and multivariate analysis with Cox's regression model was used to statistically identify the best combination of these risk factors to predict prognosis.
Results: Univariate analysis revealed tumour size, lymph node involvement and parametrial spread as significant prognostic factors for survival. Multivariate analysis showed that lymph node involvement and parametrial spread remained significant prognostic factors. Overall carcinoma with tumour size of less than 4 cms had a higher chance for survival.
Conclusion: The presence of lymph node involvement and parametrial spread decreased the chance of survival by two and a half and threefold, respectively. Lack of awareness about the screening, symptoms of disease and non-availability of early diagnostic facilities such as the Pap smear at a primary health care level are areas of priority. The most pressing need is to spread awareness among sexually active women to undergo Pap tests at regular intervals.
